Study the Effect of Nucleoside on Host Immune in Patients With CHB
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- change of programmed death-1(PD-1) level of patients with chronic HBV infection during therapy
研究概览
简要总结
During hepatitis B virus(HBV) infection host immune plays important role.Recently there are many different antiviral therapy methods.Different antiviral therapy methods showed different effector.In order to investigate whether these antiviral therapy methods especially methods directly inhibit viral replication have some effect on host immune the investigators designed these study. The investigators want to observe the change of host immune during antiviral therapy in patients with chronic HBV infection, and analyze the relationship between these changes and the antiviral effector of these drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 66 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
therapy
干预措施: Telbivudine (Drug)
结局指标
主要结局
change of programmed death-1(PD-1) level of patients with chronic HBV infection during therapy
时间窗: base line-4 weeks-12 weeks-24 weeks-end of therapy
次要结局
- Decline of hepatitis B e antigen (HBeAg) level(base line-4weeks-12weeks-24weeks-end of therapy)
研究者
Cz Li
professor
Changhai Hospital